Peptic ulcer disease

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
Tuesday, March 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
Tuesday, March 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

Human medicines European public assessment report (EPAR): Pylobactell, 13C-urea, Date of authorisation: 07/05/1998, Revision: 12, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Urea, Medical Subject Headings, Marketing, European Commission, INN, Stomach, Heartburn, Infection, Allergy, Bloating, ATC, Helicobacter pylori, International, European, Nausea, Language, Inflammation, Duodenum, Laboratory, Water, Mass spectrometry, Indigestion, Peptic ulcer disease, Gastritis, Medication, Enzyme, Select, Committee, Patient, Carbon, Ammonia, Diagnosis, Anatomy, Medicine, Ulcer, Nature, IIA, CHMP, Medical device

Human medicines European public assessment report (EPAR): Pylobactell, 13C-urea, Date of authorisation: 07/05/1998, Revision: 12, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Pylobactell, 13C-urea, Date of authorisation: 07/05/1998, Revision: 12, Status: Authorised

The Inner Circle Acknowledges, David Chua, M.D., FASGE as a Distinguished Healthcare Professional for his contributions to the Medical Field

Retrieved on: 
Monday, October 30, 2023
House at 200 West North Avenue, Colitis, American College, Mouth, Endoscopy, Gastrointestinal tract, University of Santo Tomas Faculty of Medicine and Surgery, ACG, Rush University, Pancreas, American Board of Commissioners for Foreign Missions, Wayne State University, Liver, American College of Gastroenterology, Society, Non-alcoholic fatty liver disease, Lincoln Park, Medical degree, Colonoscopy, Human, Inner circle, NASH, Wayne, Medical specialty, American Society for Gastrointestinal Endoscopy, IBS, Internal, University, Love, Peptic ulcer disease, Gastrointestinal Endoscopy, Hepatitis, Therapeutic endoscopy, Patient, Parent, Pharmaceutical industry, Gastroenterology, Crohn's disease, Medicine

OAKBROOK, Ill., Oct. 30, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, David Chua, M.D., FASGE is acknowledged as a Distinguished Healthcare Professional for his contributions to the Medical Field.

Key Points: 
  • OAKBROOK, Ill., Oct. 30, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, David Chua, M.D., FASGE is acknowledged as a Distinguished Healthcare Professional for his contributions to the Medical Field.
  • Dr. Chua pursued a Medical Degree from the University of Santo Tomas Faculty of Medicine and Surgery.
  • He is considered an expert in colonoscopy, liver, hepatitis, Crohns, and IBS and Therapeutic Endoscopy.
  • Board certified by the American Board of Internal Medicine-Internal Medicine, and Gastroenterology by the American Board of Internal Medicine- Internal Medicine and Gastroenterology.

Cranberry Marketing Committee Announces 2023 U.S. Cranberry Crop Estimate

Retrieved on: 
Monday, September 11, 2023
Exercise, UTI, Cranberry, Infection, CMC, Cardiovascular disease, Clinical trial, Cancer, Urinary tract infection, Woman, Research, Dentistry, Indigenous, Marketing, Helicobacter pylori, Proanthocyanidin, Peptic ulcer disease, Risk, Gastritis, Bacteria, FDA, Scurvy, System, Dietary supplement

WAREHAM, Mass., Sept. 11, 2023 /PRNewswire-PRWeb/ -- Cranberry Marketing Committee Announces 2023 U.S. Cranberry Crop Estimate Wareham, Mass., September 8, 2023 – At its annual summer meeting August 14, 2023, the Cranberry Marketing Committee (CMC) completed its biannual exercise of estimating the next U.S. cranberry crop production with the 2023 crop expected to be 8,165,000 100-lb barrel equivalents representing a 3.6 percent increase from 2022.

Key Points: 
  • The Cranberry Marketing Committee (CMC) completed its biannual exercise of estimating the next U.S. cranberry crop production with the 2023 crop expected to be 8,165,000 100-lb barrel equivalents representing a 3.6 percent increase from 2022.
  • WAREHAM, Mass., Sept. 11, 2023 /PRNewswire-PRWeb/ -- Cranberry Marketing Committee Announces 2023 U.S. Cranberry Crop Estimate Wareham, Mass., September 8, 2023 – At its annual summer meeting August 14, 2023, the Cranberry Marketing Committee (CMC) completed its biannual exercise of estimating the next U.S. cranberry crop production with the 2023 crop expected to be 8,165,000 100-lb barrel equivalents representing a 3.6 percent increase from 2022.
  • CMC represents more than 1,200 US Cranberry Growers in the growing regions of Wisconsin, Michigan, Minnesota, Massachusetts, Rhode Island, Connecticut, New Jersey, Washington and Oregon.
  • US cranberry growers harvest cranberries annually in the fall from more than 40,000 acres of bogs and marshes.

Corium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer's Disease Treatment ADLARITY® in Multiple Markets Across Asia

Retrieved on: 
Thursday, August 10, 2023
Health, Genetics, Managed Care, Clinical Trials, Pharmaceutical, Biotechnology, Hypersensitivity, Cholinesterase, Nausea, Bethanechol, Bradycardia, Peptic ulcer disease, Asthma, Neuromuscular blocking agents, Cholinergic, Partnership, Alzheimer's disease, Diarrhea, Gastrointestinal tract, IQVIA, Roflumilast, Skin, History, Orthostatic syncope, CNS, Heart block, Dementia, Tablet, Anesthesia, Vomiting, Enzyme inhibitor, Incidence, Patient, Chloride, Gastrointestinal bleeding, Nonsteroidal anti-inflammatory drug, FDA, Relaxation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cholinesterase inhibitor, Safety, Food, Caregiver, Pharmaceutical industry, Residential care, Dietary supplement, Corium, Donepezil, Lotus

Corium, LLC (“Corium”), a commercial-stage biopharmaceutical company leading the development and commercialization of novel neuroscience therapies, and Lotus Pharmaceutical (1795:TT; “Lotus”), a multinational pharmaceutical company, announced that the companies have entered into an exclusive Collaboration and License Agreement for ADLARITY® (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in ten markets across Asia.

Key Points: 
  • Corium, LLC (“Corium”), a commercial-stage biopharmaceutical company leading the development and commercialization of novel neuroscience therapies, and Lotus Pharmaceutical (1795:TT; “Lotus”), a multinational pharmaceutical company, announced that the companies have entered into an exclusive Collaboration and License Agreement for ADLARITY® (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in ten markets across Asia.
  • The companies expect to file for regulatory approval in some Asian markets later this year.
  • Under the terms of the agreement, Lotus will have exclusive rights to commercialize ADLARITY® in the applicable territory and will be responsible for the regulatory approval process.
  • According to IQVIA data, the market size of donepezil in the 10 markets in the territory is USD 185 Million.

Meridian Bioscience Continues Expansion of H. pylori Diagnostic Testing Solutions with FDA Clearance of Premier HpSA Flex

Retrieved on: 
Tuesday, July 25, 2023
Helicobacter pylori, Antigen, AACC, FLEX, Stomach, Peptic ulcer disease, Patient, Cleveland Clinic Journal of Medicine, Diagnosis, Gastritis, FDA, C&S, Medical device, Pharmaceutical industry, Meridian

CINCINNATI, July 25, 2023 /PRNewswire/ -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that the United States Food and Drug Administration (FDA) has cleared Premier® HpSA® FLEX™ for the diagnosis of H. pylori in both preserved and unpreserved stools.

Key Points: 
  • CINCINNATI, July 25, 2023 /PRNewswire/ -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that the United States Food and Drug Administration (FDA) has cleared Premier® HpSA® FLEX™ for the diagnosis of H. pylori in both preserved and unpreserved stools.
  • Premier HpSA Flex joins the extensive Meridian H. pylori portfolio of products that includes BreathID® (urea breath test for H. pylori), Curian® HpSA (fluorescent immuno analyzer antigen test), and ImmunoCard® Stat!
  • Meridian is committed to developing the broadest range of highly accurate gastrointestinal diagnostic solutions.
  • Meridian's Premier HpSA FLEX test is a non-invasive enzyme immunoassay used to qualitatively detect Helicobacter pylori (H. pylori) specific antigens in fresh, frozen, or preserved human fecal specimens.

Global Gastrointestinal Partnering 2016-2023: Trends, Players and Financials of Over 480 Partnerships - ResearchAndMarkets.com

Retrieved on: 
Monday, April 3, 2023
Biotechnology, Pharmaceutical, Health, Chapter Four, Appendicitis, Irritable bowel syndrome, Gastroesophageal reflux disease, Gastritis, Coeliac disease, A-Z, Abdominal pain, Research, Directory, Orientation, Peptic ulcer disease, Irritation, Chapter Three, Chapter One, Crohn's disease, Diarrhea, Chapter Two, Chapter Five, Chapter Six, Collection, Constipation, Inflammatory bowel disease, Extrapyramidal system, Hyperlink, Ulcerative colitis, Video game, Pharmaceutical industry, Music, Animal feed, Esophagitis, Malabsorption, Hernia, Ascites, Hemorrhoid, Pancreatitis, Gastroenteritis, Jaundice, Malnutrition

The "Global Gastrointestinal Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Gastrointestinal Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
  • Global Gastrointestinal Partnering 2016 to 2023 provides the full collection of gastrointestinal disease deals signed between the world's pharmaceutical and biotechnology companies since 2016.
  • Chapter 6 provides a comprehensive directory of all gastrointestinal partnering deals by specific gastrointestinal target announced since 2016.
  • In Global Gastrointestinal Partnering 2016 to 2023, available deals and contracts are listed by:

This Week in Health News: 11 Stories You Need to See

Retrieved on: 
Friday, March 10, 2023
Science, AID, Peptic ulcer disease, Planet Fitness, FreeStyle, Digital, Insulin, Nutricia North America, Food, AI, Danone, Motivation, Bureau of Oceans and International Environmental and Scientific Affairs, Use, ChatGPT, Medical device

NEW YORK, March 10, 2023 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists covering the healthcare industry stay on top of the week's most newsworthy and popular releases, here's a roundup of stories from the week that shouldn't be missed.

Key Points: 
  • The groundbreaking event, which takes place March 11 and March 12, will examine the science and storytelling around women's whole health.
  • Attendees will hear from experts and thought leaders, including Katie Couric, Maria Shriver, Christy Turlington Burns, Dr. Laurie Santos, Phoebe Robinson, Judy Greer, Dr. Piraye Yurttas Beim, Emma Lovewell, Jessi Miley-Dyer, and Jamie Wheal.
  • Health App Uses ChatGPT to Replace Human Health Coaches The AI coach provides instant answers to user questions, offers guidance and motivation, and helps them achieve their weight goals.
  • It can be customized to meet individual needs, allowing users to tailor their experience to their unique situation.

Danone Announces New Hypoallergenic Baby Formula Brand Pepticate, Now Available in the U.S.

Retrieved on: 
Monday, March 6, 2023
Peptic ulcer disease, Food allergy, Colic, DME, Health care, Nutricia North America, Infant, CMA, Food, Lactose, Vomiting, Patient, Criticism of the Food and Drug Administration, Diarrhea, Bureau of Oceans and International Environmental and Scientific Affairs, Men's EHF Champions League, Danone, EHF, FDA, Danone North America, Breast milk, Research, Parent, Amino acid-based formula, Forest Law Enforcement and Governance Program, Dairy, Dietary supplement, Birth control, Amazon

WHITE PLAINS, N.Y. and BROOMFIELD, Colo., March 6, 2023 /PRNewswire/ -- Danone North America, today announced alongside its Specialized Nutrition business, Nutricia, the availability of Pepticate in the U.S. to help support families with food allergies as the country continues to face a formula shortage.

Key Points: 
  • Sold in Europe for more than 30 years, Pepticate is Europe's #1 hypoallergenic extensively hydrolyzed baby formula for cow milk allergy.
  • *
    Danone's introduction of Pepticate to the U.S. builds on the company's existing efforts to alleviate the national formula shortage.
  • That's very important for families, since a good tasting formula may decrease the likelihood of formula refusal and repeated doctor visits."
  • The introduction of Pepticate to the U.S. is one of several steps Danone has taken to help American families navigate the baby formula shortage.